Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. PBA
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SPY
10. SKA-B

Go back to Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Madrigal Pharma (MDGL) Misses Q1 EPS by 2c

February 27, 2019 6:59 AM EST

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($0.75), $0.02 worse than the analyst estimate of ($0.73).

Madrigal made significant progress in 2018 in advancing the development of MGL-3196. We successfully completed Phase 2 studies in both NASH and dyslipidemia and expanded the Madrigal team to meet the demands of... More